Key Highlights

  • Revvity shares closed at $150.73 today, up 6.03%, near 52-week highs.
  • The rally was fueled by the launch of its GSP T1D 3plex kit, a CE-IVDR-certified diagnostic tool for population-wide type 1 diabetes risk screening in children.
  • The new product extends the company's newborn-screening platform into early childhood care.
  • A research firm raised its price target to $160 from $145 while maintaining an Outperform rating.

New Diagnostic Launch Extends the Company's Screening Platform

Revvity (NYSE:RVTY) shares closed near 52-week highs today, fueled by the launch of its GSP T1D 3plex kit, a CE-IVDR-certified diagnostic tool enabling population-wide screening for type 1 diabetes risk in children. The launch extends the company's existing newborn-screening platform into early childhood care, broadening its addressable market within pediatric diagnostics.

Analyst Price Target Increase Reinforces Momentum

Sentiment was further boosted by a research firm raising its price target to $160 from $145 while maintaining an Outperform rating, reinforcing bullish momentum even as some insiders, including the company's chief financial officer, continue routine 10b5-1 stock sales, and valuation models from other analysts flag the shares as roughly 20% overvalued. The rally extends a powerful multi-month run for Revvity, with shares now up nearly 45% over three months.

A Global Health Sciences Company

Revvity is a global health sciences company headquartered in Waltham, Massachusetts, operating in the Diagnostics and Research industry, formed in 2023 following the rebranding of PerkinElmer, which was originally founded in 1937. The company operates through two segments, Life Sciences and Diagnostics, providing instruments, reagents, software and detection and imaging technologies that support workflows from research discovery to diagnosis, including tools for genomic and proteomic analysis, high-content screening and newborn screening.